1α,25-Dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines

Clinical Cancer Research

Volumn 5, Issue 3, 1999, Pages 695-703

  Moffatt, Kirsten A ^a   Johannes, Widya U ^a   Miller, Gary J ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CARBOPLATIN; CISPLATIN; RO 25 6760; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; COLECALCIFEROL; DRUG DERIVATIVE; PLATINUM; RO 25-6760;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE; CELL PROLIFERATION; CYTOMETRY; DOSE RESPONSE; DRUG POTENTIATION; FLOW CYTOMETRY; HORMONAL REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; CELL CULTURE; CELL DIVISION; DRUG EFFECT; MALE; PATHOLOGY; PROSTATE TUMOR;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; CALCITRIOL; CARBOPLATIN; CELL CYCLE; CELL DIVISION; CHOLECALCIFEROL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; MALE; PLATINUM; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0032587095     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1999. CA Cancer J. Clin., 49: 8-31, 1999.
2. Hass, G. P., and Sakr, W. A. Epidemiology of prostate cancer. CA Cancer J. Clin., 47: 273-287, 1997.
3. Kerr, J. F., and Searle, J. Detection of cells by apoptosis during castration-induced involution of the rat prostate. Virchows Arch. B Cell Pathol., 13: 87-102, 1973.
4. Coffey, D. S., and Isaacs, J. T. Control of prostate growth. Urology, 17 (Suppl. 3): 17-24, 1981.
5. Isaacs, J. T., Lundmo, P. I., Berges, R., Martikainen, P., Kyprianou, N., and English, H. F. Androgen regulation of programmed death of normal and malignant prostatic cells. J. Androl., 13: 457-464, 1992.
6. Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., and Goodman. P. J. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med., 321: 419-424, 1989.
7. Eisenberger, M. A. Chemotherapy for prostate carcinoma. NCI Monogr., 7: 151-163, 1988.
8. Walters, M. R. Newly identified actions of the vitamin D endocrine system. Endocrinol. Rev., 13: 719-764, 1992.
9. Bickle, D. D. Clinical counterpoint: vitamin D: new actions, new analogies, new therapeutic potential. Endocr. Rev., 13: 765-784, 1992.
10. Colguere, V. Retinoic acid receptors and cellular retinoid binding proteins: complex interplay in retinoid signaling. Endocr. Rev., 15: 61-79, 1994.
11. McDonnell, D. B., Manglesdorf, D. J., Pike, W. J., Haussler, M. R., and O'Malley, B. W. Molecular cloning of complimentary DNA encoding the avian receptor for vitamin D. Science (Washington DC), 235: 1214-1217, 1987.
12. Miller, G. J., Stapleton, G. E., Houmiel, K. L., and Ferrara, J. A. Specific receptors for vitamin D in human prostatic carcinoma cells. In: J. P. Karr, D. S. Coffey, R. B. Smith, and D. J. Tindall (eds.), Molecular and Cellular Biology of Prostate Cancer, pp. 253-259. New York: Plenum Publishing Corp., 1991.
13. 3 in seven human prostatic carcinoma cell lines. Clin Cancer Res., 1: 997-1003, 1995.
14. 3 on primary cultures of human cells. Cancer Res., 54: 805-810, 1994.
15. Feldman, D., Skowronski, R. J., and Peehl, D. M. Vitamin D and prostate cancer. Adv. Exp. Med. Biol., 375: 53-63, 1995.
16. 3 receptions and actions in human prostatic cancer cell lines. Endocrinology, 132: 1952-1960, 1995.
17. Osborn, J. L., Schwartz, G. G., Smith, D., Bahnson, R., Day, R., and Trump, D. L. Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol. Oncol., 1: 195-198, 1995.
18. Gross, C., Stamey, T., Hancock, S., and Feldman, D. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J. Urology, 159: 2035-2040, 1998.
19. Schwartz, G. G, Oeler, T. A., Uskokovic, M. R., and Bahnson, R. R. Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. Anticancer Res., 14: 1077-1081, 1004.
20. Schwartz, G. G., Hill, C. C., Oeler, T. A., Becich, M. J., and Bahnson, R. R. 1,25-Dihydroxy-16-ene-23-vitamin D and prostate cancer cell proliferation in vivo. Urology, 46: 365-369, 1995.
21. Skowronski, R. J., Peehl, D. M., and Feldman, D. Actions of vitamin D analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology, 136: 20-26, 1995.
22. Hedlund, T. E., Moffatt, K. A., Uskokovic, M. R., and Miller, G. J. Three synthetic vitamin D analogues induce prostate specific acid phosphatase and prostate specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor dependent fashion. Clin. Cancer Res., 3: 1331-1338, 1997.
23. Sherman, S. E., and Lippard, S. J. Structural aspects of platinum anticancer drug interactions with DNA. Chem. Rev., 87: 1154-1181, 1987.
24. Chu, G. Cellular responses to cisplatin. J. Biol. Chem., 269: 787-790, 1994.
25. Qazi, R., and Khanderkar, J. Phase II study of cisplatin for metastatic prostatic carcinoma. An Eastern Cooperative Oncology Group study. Am. J. Clin. Oncol., 6: 203-205, 1983.
26. Merrin, C. Treatment of advanced carcinoma of the prostate (stage D) with infusion of cis-diamminedichloroplatinum (11 NSC 119875): a pilot study. J. Urol., 119: 522-524, 1978.
27. Trump, D. L., Marsh, J. C., Kvols, L. K., Citrin, D., Davis, T. E., Hahn, R. G., and Vogl, S. E. A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy. An Eastern Cooperative Group study. Invest. New Drugs, 8 (Suppl.): S91-S94, 1990.
28. Miglietta, L., Cannobbio, L., and Boccardo, F. Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a clinical analysis of drug activity. Anticancer Res., 15: 2825-2828, 1995.
29. 3 and platinum drugs on the growth of MCF-7 cells. Cancer Res., 52: 2848-2853, 1991.
30. Light, B. W., Yu, W., McElwain, M. C., Russel, D. M., Trump, D. L., and Johnson, C. S. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma system. Cancer Res., 57: 3759-3764, 1997.
31. Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H., Chu, T. M., Mirand, Z. A., and Murphy, G. P. LNCaP model of human prostatic cell carcinoma. Cancer Res., 43: 1809-1818, 1983.
32. Stone, K. R., Mickey, D. D., Wunderli, H., Mickey, G. H., and Paulson, D. F. Isolation of a human prostatic carcinoma cell line (DU-145). Int. J. Cancer, 21: 274-281, 1978.
33. Hedlund, T. E., and Miller, G. J. A serum-free defined medium capable of supporting growth of four established human prostatic carcinoma cell lines. Prostate, 24: 221-228, 1994.
34. Gessner, P. K. A straightforward method for the study of drug interactions: an isobolographic analysis primer. J. Am. Coll. Toxicol., 7: 987-1012, 1988.
35. Church, M. W., Dintcheff, B. A., and Gessner, P. K. The interactive effects of alcohol and cocaine on maternal and fetal toxicity in the Long-Evans rat. Neurotoxicol. Teratol., 10: 355-361, 1988.
36. Carter, W. H., and Wampler, G. L. Review of the application of response surface methodology in the combination therapy of cancer. Cancer Treat. Rep., 70: 133-140, 1986.
37. Berenbaum, M. C. What is synergy? Pharmacol. Rev., 41: 93-141, 1989.
38. Machado, S. G., and Robinson G. A. A direct, general approach based on isobolograms for assessing the joint action of drugs in preclinical experiments. Statistics Med., 13: 2289-2309, 1994.
39. r 170,000 glycoprotein (gp170) binding studies. Cancer Res., 54: 441-447, 1994.
40. Hedlund, T. E., Moffatt, K. A., and Miller, G. J. Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1α,25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway. Endocrinology, 137: 1554-1561, 1996.
41. Hedlund, T. E., Moffatt, K. A., and Miller, G. J. Vitamin D receptor expression is required for growth modulation by 1α,25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31. J. Steroid Biochem. Mol. Biol., 58: 277-288, 1996.
42. Lokich, J. L., and Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann. Oncol., 9: 13-21, 1998.
43. Van Veldhuizen, P., Hamilton, J., Burns, D., Drees, B., and Sadasivan, R. Vitamin D deficiency and elevation of parathyroid hormone levels in patients with advanced hormone refractory prostate cancer. Proc. Am. Assoc. Cancer Res., 39: 711, 1998.
44. Krishnaswamy, G., and Dewy, W. C. Cisplatin induced cell killing and chromosomal aberrations in CHO cells treated during G1 or S phase. Mutat. Res., 293: 161-172, 1993.
45. Donaldson, K. L., Goolsby, G. L., and Wahl, A. F. Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int. J. Cancer, 57: 847-855, 1994.
46. 1. Endocrinology, 138: 1491-1947, 1997.
47. 3 analogue involves the induction of p21(waf-1), p27(kip1), and E-cadherin. J. Mol. Endocrinol., 19: 15-27, 1997.
48. 1 accumulation. Endocrinology, 139: 1197-1207, 1998.
49. 3 on cell-cycle kinetics on T 47D human breast cancer cells. J. Cell. Physiol., 138: 611-616, 1989.
50. 3-induced monocyte differentiation. Cancer Res., 50: 1183-1188, 1990.
51. Treiber, D. K., Zhai, X., Jantzen, H. M., and Essigmann, J. M. Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). Proc. Natl. Acad. Sci. USA, 91: 5672-5676, 1994.
52. Sorenson, C. M., Barry, M. A., and Eastman, A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J. Natl. Cancer Inst., 82: 749-755, 1990.